BCL2L10 is a predictive factor for resistance to azacitidine in MDS and AML patients.

Oncotarget
Thomas CluzeauPatrick Auberger

Abstract

Azacitidine is the leading compound to treat patients suffering myelodysplastic syndrome (MDS) or AML with less than 30% of blasts, but a majority of patients is primary refractory or rapidly relapses under treatment. These patients have a drastically reduced life expectancy as compared to sensitive patients. Therefore identifying predictive factors for AZA resistance is of great interest to propose alternative therapeutic strategies for non-responsive patients. We generated AZA-resistant myeloid cell line (SKM1-R) that exhibited increased expression of BCL2L10 an anti-apoptotic Bcl-2 member. Importantly, BCL2L10 knockdown sensitized SKM1-R cells to AZA effect suggesting that increased BCL2L10 expression is linked to AZA resistance in SKM1-R. We next established in 77 MDS patients that resistance to AZA is significantly correlated with the percentage of MDS or AML cells expressing BCL2L10. In addition, we showed that the proportion of BCL2L10 positive bone marrow cells can predict overall survival in MDS or AML patients. We propose a convenient assay in which the percentage of BCL2L10 expressing cells as assessed by flow cytometry is predictive of whether or not a patient will become resistant to AZA. Therefore, systematic dete...Continue Reading

References

Mar 1, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P WijermansA Ferrant
Mar 30, 2001·The Journal of Biological Chemistry·N KeJ C Reed
Dec 16, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce D ChesonUNKNOWN International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards
Feb 20, 2004·Cancer Research·Kohichiroh YasuiJohji Inazawa
Jan 8, 2008·The Journal of Biological Chemistry·Dayong ZhaiJohn C Reed
Apr 17, 2008·Annals of Hematology·Detlef Haase
May 17, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Maryla KrajewskaJohn C Reed
Mar 4, 2009·Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology·Jae-Hong KimJeehyeon Bae
Nov 6, 2009·The New England Journal of Medicine·Ayalew Tefferi, James W Vardiman
Dec 23, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Pierre FenauxLewis R Silverman
Nov 12, 2010·The New England Journal of Medicine·Timothy J LeyRichard K Wilson
Mar 19, 2011·Leukemia·M J WalterT A Graubert
Jul 1, 2011·The New England Journal of Medicine·Rafael BejarBenjamin L Ebert
Jul 27, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Thomas PrébetNorbert Vey
Sep 13, 2011·Nature·Kenichi YoshidaSeishi Ogawa
Oct 15, 2011·The New England Journal of Medicine·E PapaemmanuilUNKNOWN Chronic Myeloid Disorders Working Group of the International Cancer Genome Consortium
Dec 14, 2011·Nature Genetics·Timothy A GraubertMatthew J Walter
Jan 12, 2012·Proceedings of the National Academy of Sciences of the United States of America·Levi J BeverlyHarold Varmus

❮ Previous
Next ❯

Citations

Feb 8, 2020·Leukemia & Lymphoma·Curtis LachowiezMarina Konopleva
Jun 2, 2020·Expert Review of Anticancer Therapy·Jonathan FeldShyamala C Navada
Nov 20, 2013·Leukemia·R Itzykson, P Fenaux
Jan 3, 2014·The Journal of Clinical Investigation·Marianne B TreppendahlKirsten Grønbæk
Nov 16, 2014·Apoptosis : an International Journal on Programmed Cell Death·Marc Kvansakul, Mark G Hinds
Oct 26, 2016·International Journal of Hematology·M Monika BelickovaAnna Jonasova
Jan 5, 2019·Leukemia·Alix DuboisGuillaume Robert
Dec 18, 2013·Current Opinion in Hematology·Amer M ZeidanRami S Komrokji
Jul 28, 2016·The Journal of Experimental Medicine·Mohamed-Amine HamoudaFrederic Luciano
Mar 31, 2016·International Journal of Molecular Sciences·Harinder GillYok-Lam Kwong
Jan 3, 2020·International Journal of Oncology·Su-Yeon LeeKyung-Ah Lee
Apr 26, 2014·American Journal of Hematology·Rami S KomrokjiJeffrey E Lancet
Jun 23, 2016·Clinical Epigenetics·Jeannine DieschKatharina S Götze
Mar 16, 2018·Expert Review of Hematology·Stephan R BohlFrank G Rücker
Dec 29, 2019·International Journal of Molecular Sciences·Thomas CluzeauPatrick Auberger
Nov 25, 2016·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Françoise SollyEric Wattel
Nov 17, 2019·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·Ana Bela Sarmento-RibeiroIoannis P Trougakos
Jan 30, 2021·Seminars in Hematology·Jesus D Gonzalez-LugoAditi Shastri
Mar 7, 2021·International Journal of Molecular Sciences·Ľuboš JanotkaAlbert Breier
Sep 1, 2021·BioEssays : News and Reviews in Molecular, Cellular and Developmental Biology·Jasmin StraubeTherese Vu

❮ Previous
Next ❯

Methods Mentioned

BETA
MDS
flow
transfection
flow cytometry
Reverse Transcription Polymerase Chain Reaction

Clinical Trials Mentioned

NCT01210274

Software Mentioned

SAS
Image J

Related Concepts

Related Feeds

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.